Barinthus Biotherapeutics PLC
BRNS1.310USD
-0.090-6.43%
Horário de mercado （ET）Cotações atrasadas em 15 min
52.84MValor de mercado
PerdaP/L TTM
Mais detalhes de Barinthus Biotherapeutics PLC Empresa
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Informações da empresa
Código da empresaBRNS
Nome da EmpresaBarinthus Biotherapeutics PLC
Data de listagemApr 30, 2021
CEOMr. William J. (Bill) Enright
Número de funcionários105
Tipo de títulosDepository Receipt
Fim do ano fiscalApr 30
EndereçoUnit 6-10, Zeus Building, Rutherford Avenue
CidadeDIDCOT
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalOX11 0DF
Telefone441865818808
Sitehttps://www.barinthusbio.com/
Código da empresaBRNS
Data de listagemApr 30, 2021
CEOMr. William J. (Bill) Enright
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 4 de jul
Atualizado em: sex, 4 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Investidores
Investidores
Proporção
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Tipos de investidores
Investidores
Proporção
Venture Capital
25.56%
Investment Advisor
18.09%
Individual Investor
13.54%
Corporation
0.92%
Investment Advisor/Hedge Fund
0.53%
Endowment Fund
0.30%
Hedge Fund
0.15%
Research Firm
0.04%
Other
40.87%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
40
23.85M
59.13%
+716.00K
2025Q1
41
23.85M
60.03%
+745.95K
2024Q4
40
24.08M
59.87%
+1.54M
2024Q3
37
20.03M
50.21%
-349.60K
2024Q2
38
20.26M
51.12%
-213.80K
2024Q1
38
20.04M
50.62%
-468.31K
2023Q4
42
19.97M
51.73%
-616.84K
2023Q3
45
19.96M
51.78%
-695.67K
2023Q2
52
20.10M
52.29%
-1.03M
2023Q1
51
20.44M
53.30%
-692.87K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Oxford Science Enterprises PLC
8.80M
21.81%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.88%
--
--
Mar 31, 2025
Cawood (Frank Wayne)
3.38M
8.39%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.75%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.42M
3.52%
--
--
Mar 31, 2025
Enright (William)
1.24M
3.08%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.59%
--
--
Mar 31, 2025
Lynn (Geoffrey)
638.44K
1.58%
+638.44K
--
Dec 17, 2024
Gilead Sciences Inc
369.86K
0.92%
-250.50K
-40.38%
Mar 31, 2025
Johns Hopkins University
122.24K
0.3%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
